Maxim Pharmaceuticals cancer drug disappoints in trials SAN DIEGO - Shares of Maxim Pharmaceuticals Inc. nearly halved in value Monday, following news that its Ceplene drug failed to improve survival in a trial of patients with malignant melanoma where the cancer had spread to the liver.